Altered brain penetration of diclofenac and mefenamic acid, but not acetaminophen, in shiga-like toxin II-treated mice

Journal of Pharmacological Sciences

Volumn 97, Issue 4, 2005, Pages 525-532

  Fukuda, Masaya ^a   Kitaichi, Kiyoyuki ^a   Abe, Fumie ^a   Fujimoto, Yohei ^a   Takagi, Kenji ^a   Takagi, Kenzo ^a   Morishima, Tsuneo ^b   Hasegawa, Takaaki ^c  

^a NAGOYA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood brain barrier; Cyclooxygenase inhibitor; Organic anion transporter; Shiga like toxin II

Indexed keywords

ANION TRANSPORT PROTEIN; ANTIPYRETIC AGENT; CYTOKINE; DICLOFENAC; MEFENAMIC ACID; ORGANIC ANION TRANSPORTER; PARACETAMOL; PROBENECID; PROSTAGLANDIN SYNTHASE INHIBITOR; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANION TRANSPORT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN; BRAIN INFECTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; ESCHERICHIA COLI O157; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 18244386468     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FP0040752     Document Type: Article

References (39)

1. Waldman RJ, Hall WN, McGee H, Van Amburg G. Aspirin as a risk factor in Reye's syndrome. JAMA. 1982;247:3089-3094.
2. Kasai T, Togashi T, Morishima T. Encephalopathy associated with influenza epidemics. Lancet. 2000;355:1558-1559.
3. Morishima T, Togashi T, Yokota S, Okuno Y, Miyazaki C, Tashiro M, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002;35:512-517.
4. Ichiyama T, Isumi H, Ozawa H, Matsubara T, Morishima T, Furukawa S. Cerebrospinal fluid and serum levels of cytokines and soluble tumor necrosis factor receptor in influenza virus-associated encephalopathy. Scand J Infect Dis. 2003;35:59-61.
5. Kawada J, Kimura H, Ito Y, Hara S, Iriyama M, Yoshikawa T, et al. Systemic cytokine responses in patients with influenza-associated encephalopathy. J Infect Dis. 2003;188:690-698.
6. Kawashima H, Watanabe Y, Morishima T, Togashi T, Yamada N, Kashiwagi Y, et al. NOx (nitrite/nitrate) in cerebral spinal fluids obtained from patients with influenza-associated encephalopathy. Neuropediatrics. 2003;34:137-140.
7. Kang YS, Ohtsuki S, Takanaga H, Tomi M, Hosoya K, Terasaki T. Regulation of taurine transport at the blood-brain barrier by tumor necrosis factor-α, taurine and hypertonicity. J Neurochem. 2002;83:1188-1195.
8. Strazielle N, Khuth ST, Murat A, Chalon A, Giraudon P, Belin MF, et al. Pro-inflammatory cytokines modulate matrix metalloproteinase secretion and organic anion transport at the blood-cerebrospinal fluid barrier. J Neuropathol Exp Neurol. 2003;62:1254-1264.
9. Theron D, Barraud de Lagerie S, Tardivel S, Pelerin H, Demeuse P, Mercier C, et al. Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochem Pharmacol. 2003;66:579-587.
10. Kita E, Yunou Y, Kurioka T, Harada H, Yoshikawa S, Mikasa K, et al. Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7. Infect Immun. 2000;68:1207-1214.
11. Zhao YL, Du J, Kanazawa H, Cen XB, Takagi K, Kitaichi K, et al. Shiga-like toxin II modifies brain distribution of a P-glycoprotein substrate, doxorubicin, and P-glycoprotein expression in mice. Brain Res. 2002;956:246-253.
12. Zhao YL, Cen XB, Ito M, Yokoyama K, Takagi K, Kitaichi K, et al. Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats. Antimicrob Agents Chemother. 2002;46:1522-1528.
13. Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Adv Drug Deliv Rev. 2003;55:83-105.
14. Graff CL, Pollack GM. Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab. 2004;5:95-108.
15. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-166.
16. Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, et al. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002;303:534-539.
17. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem. 2002;277:26934-26943.
18. Kojima R, Sekine T, Kawachi M, Cha SH, Suzuki Y, Endou H. Immunolocalization of multispecific organic anion transporters, OAT1, OAT2, and OAT3, in rat kidney. J Am Soc Nephrol. 2002;13:848-857.
19. Choudhuri S, Cherrington NJ, Li N, Klaassen CD. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab Dispos. 2003;31:1337-1345.
20. Masuda S, Saito H, Inui K. Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-K1. J Pharmacol Exp Ther. 1997;283:1039-1042.
21. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y. Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001;298:1179-1184.
22. Sugiyama D, Kusuhara H, Taniguchi H, Ishikawa S, Nozaki Y, Aburatani H, et al. Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine. J Biol Chem. 2003;278:43489-43495.
23. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, et al. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002;19:147-153.
24. Emoto A, Ushigome F, Koyabu N, Kajiya H, Okabe K, Satoh S, et al. H(+)-linked transport of salicylic acid, an NSAID, in the human trophoblast cell line BeWo. Am J Physiol Cell Physiol. 2002;282:1064-1075.
25. Santamaria A, Rios C, Solis-Hernandez F, Ordaz-Moreno J, Gonzalez-Reynoso L, Altagracia M, et al. Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology. 1996;35:23-28.
26. Cox DS, Scott KR, Gao H, Raje S, Eddington ND. Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anti-convulsants. J Pharm Sci. 2001;90:1540-1552.
27. Hirai T, Matsumoto S, Kishi I. Simultaneous analysis of several non-steroidal anti-inflammatory drugs in human urine by high-performance liquid chromatography with normal solid-phase extraction. J Chromatogr B Biomed Sci Appl. 1997;692:375-388.
28. Mikami E, Goto T, Ohno T, Matsumoto H, Inagaki K, Ishihara H, et al. Simultaneous analysis of anthranilic acid derivatives in pharmaceuticals and human urine by high-performance liquid chromatography with isocratic elution. J Chromatogr B Biomed Sci Appl. 2000;744:81-89.
29. Alkharfy KM, Frye RF. High-performance liquid chromatographic assay for acetaminophen glucuronide in human liver microsomes. J Chromatogr B Biomed Sci Appl. 2001;753:303-308.
30. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem. 1999;47:1255-1264.
31. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, et al. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002;83:57-66.
32. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, et al. Characterization of the efflux transport of 17beta-estradiol-D-17beta- glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001;298:316-322.
33. Galinsky RE, Flaharty KK, Hoesterey BL, Anderson BD. Probenecid enhances central nervous system uptake of 2′,3′-dideoxyinosine by inhibiting cerebrospinal fluid efflux. J Pharmacol Exp Ther. 1991;257:972-978.
34. Kikuchi R, Kusuhara H, Sugiyama D, Sugiyama Y. Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J Pharmacol Exp Ther. 2003;306:51-58.
35. Nagata Y, Kusuhara H, Endou H, Sugiyama Y. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002;61:982-988.
36. Hosoya K, Ohtsuki S, Terasaki T. Recent advances in the brain-to-blood efflux transport across the blood-brain barrier. Int J Pharm. 2002;248:15-29.
37. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999;274:13675-13680.
38. Kitaichi K, Nakayama H, Ueyama J, Nadai M, Baba K, Takagi K, et al. Down-regulation of cytochrome P450 proteins and its activities by Shiga-like toxin II from Escherichia coli O157:H7. Biochem Pharmacol. 2004;67:1427-1435.
39. Zhao YL, Du J, Kanazawa H, Sugawara A, Takagi K, Kitaichi K, et al. Effect of endotoxin on doxorubicin transport across blood-brain barrier and P-glycoprotein function in mice. Eur J Pharmacol. 2002;445:115-123.